Global spine biologics market generated revenue of $1,644 million in 2015, and is projected to reach $2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. Increase in geriatric population, advantages of biologics such as minimal postoperative time, faster recovery, and their ability to activate cellular growth are the factors that drive the market growth. However, unfavorable reimbursement scenario, higher cost of the bone grafts, and certain ethical issues related to bone grafting procedures are expected to restrain the growth of the market. Research Beam Model: Research Beam Product ID: 2704004 5370 USD New
Spine Biologics Market by Product (Spinal Allografts, Bone Graft Substitutes, and Cell Based Matrix) and Surgery (Open Spine Surgery and Minimally Invasive Spine Surgery) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Spine Biologics Market by Product (Spinal Allografts, Bone Graft Substitutes, and Cell Based Matrix) and Surgery (Open Spine Surgery and Minimally Invasive Spine Surgery) - Global Opportunity Analysis and Industry Forecast, 2014-2022

 
  • Category : Healthcare
  • Published On : March  2017
  • Pages : 174
 
 

Global spine biologics market generated revenue of $1,644 million in 2015, and is projected to reach $2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. Increase in geriatric population, advantages of biologics such as minimal postoperative time, faster recovery, and their ability to activate cellular growth are the factors that drive the market growth. However, unfavorable reimbursement scenario, higher cost of the bone grafts, and certain ethical issues related to bone grafting procedures are expected to restrain the growth of the market.

Biologics are used during spinal fusion procedure, as they stimulate bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, rise in number of spinal fusion surgery boosts the use of biologics.

Increase in geriatric population is the major factor anticipated to fuel the demand for biologics in future. For instance, spinal disorders such as spinal stenosis is the most common problem in men and women over 50 years. Aging leads to structural alterations in spine such as thickening of the band of the tissue that supports the spine and enlargement of bones & joints, thus resulting in spinal impairment. According to “Eurostat”, the population of the European Union (EU) was estimated to be 508.5 million on January 1, 2015. Aged population (65 or over) had a share of 18.9%, which showed an increase of 0.4% compared to the previous year. Therefore, older people who are at a higher risk to develop spinal deformities have increased chances to undergo spinal fusion surgery, which in turn is projected to increase the demand for spine biologics.

Key Benefits of the Report

  • The study provides an in-depth analysis of the global spine biologics market with current trends and future estimations to elucidate the imminent investment pockets.
  • Quantitative analysis from 2014 to 2022 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • The report provides actual historical figures for 2014 and Y-o-Y forecasts from 2016 to 2022, considering 2015 as base.
  • Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these geographies.
  • Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Spine Biologics Market Key Segments

By Product

  • Spinal Allografts
    • Machined Bones Allograft
    • Demineralized Bone Matrix
  • Bone Graft Substitutes
    • Bone Morphogenetic Proteins
    • Synthetic Bone Grafts
  • Cell based Matrix

By Surgery

  • Open Spine Surgery
  • Minimally Invasive Spine Surgery

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. Key Benefits
1.2. Key Market Segments
1.3. Key Players
1.4. Research Methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. Key Findings Of The Study
2.2. CXO Perspective

CHAPTER 3 MARKET OVERVIEW

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top winning strategies

3.2.1.1. Competitive intelligence and strategies of companies

3.2.2. Top investment pockets

3.3. Market Share Analysis, 2015
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Growing elderly population
3.4.1.2. Increasing prevalence of spinal disorders
3.4.1.3. Advantages of biologic materials
3.4.1.4. Shift towards minimal invasive spine procedures

3.4.2. Restraints

3.4.2.1. Higher cost
3.4.2.2. Ethical issues related to grafting

3.4.3. Opportunities

3.4.3.1. Emerging markets to drive the demand for spine biologics

3.4.4. Impact analysis

3.5. Porter's Five Force's Analysis

3.5.1. Bargaining power of buyers
3.5.2. Bargaining power of suppliers
3.5.3. Threat of substitutes
3.5.4. Threat of new entrants
3.5.5. Competitive rivalry

3.6. Government Regulations

CHAPTER 4 GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.1.4. Global Spine Biologic Implantations, By Type
4.1.5. Spinal allografts

4.1.5.1. Market size and forecast

4.1.5.1.1. Machined bone allograft

4.1.5.1.1.1. Market size and forecast

4.1.5.1.2. Demineralized bone matrix

4.1.5.1.2.1. Market size and forecast

4.1.6. Bone graft substitutes

4.1.6.1. Market size and forecast

4.1.6.1.1. Bone morphogenetic proteins

4.1.6.1.1.1. Market size and forecast

4.1.6.1.2. Synthetic bone grafts

4.1.6.1.2.1. Market size and forecast

4.1.7. Cell based matrix

4.1.7.1. Market size and forecast

CHAPTER 5 GLOBAL SPINAL IMPLANTS AND DEVICES MARKET, BY SURGERY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. Open Spine Surgery

5.2.1. Market size and forecast

5.3. Minimally Invasive Spine Surgery

5.3.1. Market size and forecast

CHAPTER 6 GLOBAL SPINE BIOLOGICS MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size and forecast
6.2.5. Canada market size and forecast
6.2.6. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. France market size and forecast
6.3.5. Germany market size and forecast
6.3.6. UK market size and forecast
6.3.7. Spain market size and forecast
6.3.8. Italy market size and forecast
6.3.9. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. India market size and forecast
6.4.5. China market size and forecast
6.4.6. Japan market size and forecast
6.4.7. South Korea market size and forecast
6.4.8. Australia market size and forecast
6.4.9. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size and forecast
6.5.5. Saudi Arabia market size and forecast
6.5.6. South Africa market size and forecast
6.5.7. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ALPHATEC HOLDINGS, INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating product categories
7.1.4. Business Performance
7.1.5. Key strategic moves and developments

7.2. EXACTECH, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Key strategic share

7.3. JOHNSON & JOHNSON

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. GLOBUS MEDICAL, INC.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating product categories
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Key strategy share

7.5. MEDTRONIC PLC

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Key strategy share

7.6. NUVASIVE, INC.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Key strategy share

7.7. ORTHOFIX INTERNATIONAL N.V.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Key strategy share

7.8. RTI SURGICAL, INC.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Key strategy share

7.9. SEASPINE

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Key strategy share

7.10. ZIMMER BIOMET HOLDINGS, INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Key strategy share

LIST OF TABLES

TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 2. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 3. GLOBAL SPINE BIOLOGICS IMPLANTATIONS, BY TYPE (THOUSAND UNITS), 2014-2022
TABLE 4. GLOBAL SPINAL ALLOGRAFT MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 5. GLOBAL BONE GRAFT SUBSTITUTES MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 6. GLOBAL SPINE BIOLOGICS MARKET, BY SURGERY TYPE ($MILLION), 2014-2022
TABLE 7. GLOBAL OPEN SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 8. GLOBAL MINIMALLY INVASIVE SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 9. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 11. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 12. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 13. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 14. ALPHATEC: COMPANY SNAPSHOT
TABLE 15. ALPHATEC: PRODUCT CATEGORIES
TABLE 16. EXACTECH: COMPANY SNAPSHOT
TABLE 17. EXACTECH: BUSINESS SEGMENTS
TABLE 18. J&J: COMPANY SNAPSHOT
TABLE 19. J&J: BUSINESS SEGMENTS
TABLE 20. GLOBUS MEDICAL: COMPANY SNAPSHOT
TABLE 21. GLOBUS MEDICAL: PRODUCT CATEGORIES
TABLE 22. MEDTRONIC: COMPANY SNAPSHOT
TABLE 23. MEDTRONIC: BUSINESS SEGMENTS
TABLE 24. NUVASIVE: COMPANY SNAPSHOT
TABLE 25. NUVASIVE: BUSINESS SEGMENTS
TABLE 26. ORTHOFIX: COMPANY SNAPSHOT
TABLE 27. ORTHOFIX: BUSINESS SEGMENTS
TABLE 28. RTI: COMPANY SNAPSHOT
TABLE 29. RTI: BUSINESS SEGMENTS
TABLE 30. SEASPINE: COMPANY SNAPSHOT
TABLE 31. SEASPINE: BUSINESS SEGMENTS
TABLE 32. ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 33. ZIMMER BIOMET: BUSINESS SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2015 VS 2022
FIGURE 2. MARKET SEGMENTATION
FIGURE 3. TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4. TOP WINNING STRATEGIES, ORGANIC AND INORGANIC
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DEVELOPMENT STRATEGIES ADOPTED BY COMPANIES
FIGURE 7. TOP INVESTMENT POCKETS
FIGURE 8. MARKET SHARE ANALYSIS, 2015
FIGURE 9. LOW BACK PAIN HEALTH CARE VISITS PER 100 PERSONS, U.S., 2010
FIGURE 10. BARGAINING POWER OF BUYERS, 2015
FIGURE 11. BARGAINING POWER OF SUPPLIERS
FIGURE 12. THREAT OF SUBSTITUTES
FIGURE 13. THREAT OF NEW ENTRANTS
FIGURE 14. COMPETITIVE RIVALRY
FIGURE 15. SPINE BIOLOGICS MARKET FOR MACHINED ALLOGRAFTS ($MILLION), 2014-2022
FIGURE 16. SPINE BIOLOGICS MARKET FOR DEMINERALIZED BONE MATRIX ($MILLION), 2014-2022
FIGURE 17. SPINE BIOLOGICS MARKET FOR BMP ($MILLION), 2014-2022
FIGURE 18. SPINE BIOLOGICS MARKET FOR SYNTHETIC BONE GRAFTS ($MILLION), 2014-2022
FIGURE 19. SPINE BIOLOGICS MARKET FOR CELL BASED MATRIX ($MILLION), 2014-2022
FIGURE 20. FUSION PROCEDURES IN U.S.
FIGURE 21. DISTRIBUTION OF SPINE FUSION PROCEDURE BY SPINE SECTION FOR HOSPITAL DISCHARGE PATIENTS, U.S., 2011
FIGURE 22. U.S.: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 23. CANADA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 24. MEXICO: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 25. POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 26. FRANCE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 27. GERMANY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 28. UK: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 29. SPAIN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 30. ITALY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 31. REST OF EUROPE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 32. INDIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 33. CHINA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 34. JAPAN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 35. SOUTH KOREA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 36. AUSTRALIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 37. REST OF ASIA-PACIFIC: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 38. BRAZIL: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 39. SAUDI ARABIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 40. SOUTH AFRICA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 41. REST OF LAMEA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022